April Honkanen
Family · Saint James, NYNPI 1346593225
Payments from drug & device makers
Across 85 payments — averaging $24.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$400
- Novo Nordisk$231
- AstraZeneca$213
- Amgen$188
- GSK$178
- Merck$141
- plus $747 from 14 others
What the payments were for
- Food & beverage$2,096100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $400 |
| Novo Nordisk | 12 | $231 |
| AstraZeneca | 7 | $213 |
| Amgen | 3 | $188 |
| GSK | 4 | $178 |
| Merck | 7 | $141 |
| Novartis | 6 | $136 |
| Pfizer | 7 | $129 |
| Astellas Pharma US Inc | 6 | $105 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $83 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $74 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Boston Scientific | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Lundbeck LLC | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| Exact Sciences | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,096 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 37 | $45,679 |
| OzempicSemaglutide | 23 | $27,508 |
| FarxigaDapagliflozin Propanediol | 16 | $24,639 |
| JanuviaSitagliptin Phosphate | 18 | $17,237 |
| EntrestoSacubitril/Valsartan | 12 | $12,999 |
| Niacin ErNiacin | 11 | $2,014 |
| Rosuvastatin Calcium | 92 | $1,751 |
| Atorvastatin Calcium | 97 | $1,413 |
| Nebivolol Hcl | 13 | $1,141 |
| SynthroidLevothyroxine Sodium | 12 | $790 |
| Olmesartan Medoxomil | 30 | $675 |
| Ezetimibe | 27 | $644 |
| Levothyroxine Sodium | 54 | $601 |
| Pantoprazole Sodium | 36 | $592 |
| Amlodipine Besylate | 54 | $555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $129 | $45,67937 claims |
| Novo NordiskOzempic | $231 | $27,50823 claims |
| AstraZenecaFarxiga | $213 | $24,63916 claims |
| MerckJanuvia | $141 | $17,23718 claims |
| NovartisEntresto | $136 | $12,99912 claims |
| AbbVieSynthroid | $400 | $79012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.
Other family in Saint James
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.